TMCnet News
TAURIGA SCIENCES, INC. FILES (8-K) Disclosing Change in Directors or Principal Officers, Financial Statements and Exhibits(Edgar Glimpses Via Acquire Media NewsEdge) ITEM 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers On October 24, 2014, Michael J. Brennan, M.D., Ph.D. was appointed as a member of the Board of Directors (the "Board") of Tauriga Sciences, Inc. (the "Company"). On October 27, 2014, Dr. Brennan was also appointed to serve as member of the Compensation Committee of the Board. Dr. Brennan currently serves as the Managing Director of Pearl Street Venture Funds, a venture capital firm, a position he has held since 2006. From December 2003 until December 2005, Dr. Brennan was a Managing Director of Coastview Capital, a venture capital firm focused exclusively on life science investments. From September 2000 until April 2003, Dr. Brennan was a General Partner of Oxford Biosciences Partners, a venture capital firm specializing in the financing of early stage healthcare companies. From 1996 until 2000, Dr. Brennan served as the Chief Executive Officer and member of the Board of Directors of Gene Logic Inc., a publicly traded company. Dr. Brennan received a Ph.D. in neurobiology and an M.D. from the University of Witwatersrand, Johannesburg, South Africa. Family Relationships There are no family relationships between any of the Company's directors or officers and Dr. Brennan. Related Party Transactions There are no related party transactions with respect to Dr. Brennan reportable under Item 5.02 of Form 8-K and Item 404(a) of Regulation S-K. Compensatory Arrangements On October 24, 2014, Dr. Brennan was granted 1,000,000 shares of the Company's common stock, par value $0.001. All such shares are "restricted securities" as such term is defined by the Securities Act of 1933, as amended. The Company has not entered into any other compensatory agreements or plan with Dr. Brennan. ITEM 9.01 Financial Statements and Exhibits Exhibit No. Description of Exhibit 99.1* Press release issued on October 30, 2014 *filed herewith |